Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World June 18, 2008 Ananyo Bhattacharya	Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
Pharmaceutical Executive April 1, 2007 Sarah Houlton	Global Report: If It Ain't Broke Under the UK's pricing scheme, drug prices have dropped by 21% in 10 years. Is it really time for a change?
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
Chemistry World April 2007 Richard Barker	Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago.
Pharmaceutical Executive May 1, 2011 Julian Upton	UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.
Pharmaceutical Executive May 1, 2012	Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity?
Pharmaceutical Executive August 1, 2008 Sarah Houlton	Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Pharmaceutical Executive August 1, 2012 Leela Barham	The Queen's English Defining the language of value based pricing in the United Kingdom and ultimately the world.
Pharmaceutical Executive December 1, 2006 Sarah Houlton	Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Chemistry World March 17, 2014 Phillip Broadwith	UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
Chemistry World May 4, 2006 Katharine Sanderson	Cancer Charity Takes on Shelved Drugs Cancer Research UK, and its commercial arm, Cancer Research Technology have launched a clinical development partnership scheme to sweep up drug candidates that pharmaceuticals companies have deprioritized for not showing enough commercial promise.
Chemistry World July 2010	Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon
Pharmaceutical Executive October 1, 2008 Sarah Houlton	Open For Debate Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems.
Pharmaceutical Executive June 1, 2013 Julian Upton	Opening the Patent Box Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box," which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property.
The Motley Fool December 30, 2010 Brian Orelli	This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly.
Chemistry World May 2006 Bea Perks	Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation.
Chemistry World May 15, 2009 Katrina Megget	Tripping over red tape The UK may be moving a step closer to allowing the use of a cannabis-based drug to treat the symptoms of multiple sclerosis
Chemistry World December 8, 2011 Maria Burke	Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry.
Pharmaceutical Executive October 1, 2014 Leela Barham	The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine.
Pharmaceutical Executive June 1, 2007 Sarah Houlton	Global Report: Single-Source Supply Pfizer's move to consolidate its drug supply chain in the United Kingdom may signal safer - but more expensive - drugs.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
Chemistry World April 16, 2010 Sean Milmo	Ineos starts UK chemicals exodus Ineos's decision to relocate its headquarters to Switzerland because of corporate taxation concerns may spark an exodus of chemical and pharmaceutical companies from having their headquarters in the UK.
Pharmaceutical Executive February 4, 2011 William Looney	The Night Stalkers: Keeping CEOs Awake in 2011 The consensus is that 2011 will be a bad year for Big Pharma. Let's inventory a few of the 'night stalkers -- issues that are likely to keep members of the C-suite awake beyond a sensible 'lights out' time.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
Chemistry World September 22, 2006	Monitoring Environmental Risks of Nanotech The UK government's Department for Environment, Food and Rural Affairs has launched a scheme to assess the potential risks of nanotechnology.
Chemistry World April 23, 2013 Emma Stoye	Invest in research or be left behind, UK academies warn The UK's four national academies have called on the government to increase investment in research over the next decade or risk being overtaken by international competitors.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Chemistry World March 22, 2012 Andrew Turley	GSK to build 350 million factory in UK GlaxoSmithKline has announced plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria.
Chemistry World April 21, 2009 Matt Wilkinson	Survival of the fittest While the pharmaceutical and biopharmaceutical sectors in general are outperforming broader stock market trends, many early stage companies are desperately trying to conserve cash and raise money to keep going.
Chemistry World March 8, 2011 Andy Extance	GSK will pay off UK graduate tuition fees Potential undergraduate chemistry students concerned about their prospects in the face of plant closures and increased tuition fees have been given some cheer by pharmaceutical giant GlaxoSmithKline.
Pharmaceutical Executive May 1, 2006 Sarah Houlton	Global Report: A Hope and a Payer If current trends continue, the United Kingdom will spend 12.7 percent of its GDP on healthcare by 2050. Maybe that means it's time to reform the National Health Service's notoriously complex drug payment scheme.
Chemistry World February 9, 2007 Simon Hadlington	Foreign Postgrad Vetting Proposals 'Absolutely Unnecessary' A controversial new scheme for vetting foreign postgraduate students wishing to study in the UK has been slammed as 'absolutely unnecessary, completely over-the-top and counter-productive' by a leading member of parliament.
Pharmaceutical Executive November 1, 2005 Sarah Houlton	Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations.
Chemistry World July 27, 2011 Sean Milmo	UK government sets aside 1000 places for top researchers The UK chemistry sector has given a mostly cool response to a government scheme to attract top chemists, chemical engineers and other scientists from outside the EU, while tightening restrictions on immigration.
Chemistry World November 6, 2013 Laura Howes	Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D.
Chemistry World November 25, 2010 Mike Brown	Capping scientific migrants A new UK immigration cap could bias against researchers looking to come to the UK.
Chemistry World December 13, 2013 Maria Burke	UK overtakes US on research quality metric The UK has overtaken the US and now ranks first in one indicator of research quality, according to a new report commissioned by the UK's Department of Business, Innovation and Skills.
Chemistry World April 22, 2009 Matt Wilkinson	Darling budgets for high tech growth Alistair Darling, the UK's Chancellor of the Exchequer, gave a speech which focused heavily on how he wants to produce a 'hi tech Britain that will lead our economic recovery'
Chemistry World February 6, 2014 Patrick Walter	Clouds on the horizon for UK science The UK needs to up its game to keep up with the rest of the continent when it comes to science, Europe's research chief has said.
Chemistry World January 11, 2012 Hayley Birch	Drive towards detecting drugs at the roadside The UK government is setting up an advisory panel that will assess the feasibility of roadside testing for drug driving, similar to testing for drunk driving.
Chemistry World October 24, 2006 Victoria Gill	British Scholarship Scheme to Attract the World's Best Brains The Royal Society has developed an international fellowship scheme that aims to attract the world's best scientists to the UK and give the country a business edge.
Chemistry World February 26, 2013 Simon Perks	UK top scientist immigration policy under fire While Prime Minister David Cameron was away promoting the UK to Indian businesses and students, his stance on immigration was coming under increasing fire at home.
Chemistry World September 8, 2010 Andrew Turley	Vince Cable: science cuts are coming Taxpayers should only back research that makes money or is academically exceptional, UK business secretary Vince Cable said today in his first speech on science.
Chemistry World February 10, 2015 Emma Stoye	Science societies urge next UK government to invest more in research The next UK government should invest twice as much in research, according to a joint statement released by the National Academies.
Chemistry World March 2009 James Mitchell Crow	Editorial: Great debate Are university-based researchers about to receive a huge windfall? Or could blue-skies research - which by its very nature needs a free reign from government funders - become the next victim?